Previous Study: TRIO031
Next Study: TRIO029

Studies & Results

TRIO030

A Presurgical Tissue-Acquisition Study to Evaluate Molecular Alterations in Human Breast Cancer Tissue Following Short-Term Exposure to the Androgen Receptor Antagonist ODM-201

View FDA Study

Presentations

SABCS 2017

Mackey JR, Eiermann W, Fresco R, Fung H, Carrez S, Lopez C, Slamon DJ

A Presurgical Tissue-Acquisition Study to Evaluate Molecular Alterations in Human Breast Cancer Tissue Following Short-Term Exposure to the Androgen Receptor Antagonist ODM-201 (darolutamide)

ESMO 2019

Chen DH-W, Von Euw E, Millán P, Fresco R, Carrez S, Afenjar K, Fung H, Burton M, Santiago A, Guzman R, Villalobos I, Press M, Eiermann W, Slamon D.

Results from TRIO030, a Pre-Surgical Tissue-Acquisition Study to Evaluate Molecular Alterations in Human Breast Cancer Tissue Following Short-Term Exposure to the Androgen Receptor Antagonist Darolutamide

For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at valerie.bee@trioncology.org